Based on our proprietary platform technology, we are building a strong pipeline of compounds with a wide range of applications. We plan to focus on the development of our most advanced product candidate, inarigivir soproxil, for the treatment of hepatitis B virus and SB 11285, an immunotherapeutic agent for the treatment of cancers through the activation of the STING pathway.